$KYMR News

Last published 1w ago

1w agoKYMRKymira Therapeutics Third Quarter 2026 Results Call - KYMERA THERAPEUTICS INCEarnings Call Transcriptsgood day everyone my name is shell and i will be your conference operator today at this time i would like to welcome you to the chimera therapeutic third quarter 2026 results call all lines have been placed on mute to pr
1w agoKYMRKYMERA THERAPEUTICS THIRD QUARTER 2026 RESULTS CALL - KYMERA THERAPEUTICS INCEarnings Call Transcriptsgood day everyone my name is shell and i will be your conference operator today at this time i would like to welcome you to the chimera therapeutic third quarter 2026 results call all lines have been placed on mute to pr
1w agoKYMRKymera Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoKYMRKymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer TrialGlobeNewswireKT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile KT-579 LUMORA Phase 1b trial in lupus
2w agoKYMRKymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026GlobeNewswireWATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
2w agoKYMRKymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026GlobeNewswireWATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
1mo agoKYMRKuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ:...
1mo agoKYMRKYMERA THERAPEUTICS, INC. - KYMERA THERAPEUTICS INCEarnings Call TranscriptsGood morning again, everyone. Thanks for joining us for the next Fireside Chat. We have Chimera Therapeutics CEO and founder, Nella Wainolfi, and CMO, Terence Rooney, for Fireslide. Maybe I'll kick it over to Nella for a
1mo agoKYMRSTIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - KYMERA THERAPEUTICS INCEarnings Call TranscriptsGood morning again, everyone. Thanks for joining us for the next Fireside Chat. We have Chimera Therapeutics CEO and founder, Nella Wainolfi, and CMO, Terence Rooney, for Fireslide. Maybe I'll kick it over to Nella for a
1mo agoKYMRMorgan Stanley 24th Annual Global Healthcare Conference - KYMERA THERAPEUTICS INCEarnings Call TranscriptsAll right. Good morning, everyone. Thanks for being here on day two of the Morgan Stanley Global Healthcare Conference. We're very excited to have the team from Chimera here for this session. Let me just get a quick disc
1mo agoKYMRMorgan Stanley 24th Annual Global Healthcare Conference - KYMERA THERAPEUTICS INCEarnings Call TranscriptsAll right. Good morning, everyone. Thanks for being here on day two of the Morgan Stanley Global Healthcare Conference. We're very excited to have the team from Chimera here for this session. Let me just get a quick disc
2mo agoKYMRWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - KYMERA THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I think we'll get started here with the first fireside of the day. My name is Derek Archilla. I'm one of the Wells Fargo biotech analysts. I'm very excited to have Chimera Therapeutics. We from th
2mo agoKYMRWells Fargo 21st Annual Healthcare Conference - KYMERA THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I think we'll get started here with the first fireside of the day. My name is Derek Archilla. I'm one of the Wells Fargo biotech analysts. I'm very excited to have Chimera Therapeutics. We from th
2mo agoKYMRKymera Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireWATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for
2mo agoKYMRKymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology CongressesGlobeNewswireEnrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline
3mo agoKYMRKymera Therapeutics Second Quarter 2026 Results Call - KYMERA THERAPEUTICS INCEarnings Call Transcripts🎵 We'll be right back. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. We'll see you next time. Thank yo
3mo agoKYMRKYMERA THERAPEUTICS SECOND QUARTER 2026 RESULTS CALL - KYMERA THERAPEUTICS INCEarnings Call Transcripts🎵 We'll be right back. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. We'll see you next time. Thank yo
3mo agoKYMRKYMERA THERAPEUTICS SECOND QUARTER 2026 RESULTS CALL - KYMERA THERAPEUTICS INCEarnings Call Transcripts🎵 We'll be right back. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. We'll see you next time. Thank yo
3mo agoKYMRKymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdateGlobeNewswireEnrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621
3mo agoKYMRKymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026GlobeNewswireWATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
3mo agoKYMRKymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical OfficerGlobeNewswireDr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight
3mo agoKYMRKuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ:...
3mo agoKYMRKuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ:KYMR) breached their
4mo agoKYMRKymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 DegraderGlobeNewswireDr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027,
4mo agoKYMRKymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026GlobeNewswireBROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be
4mo agoKYMRKymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of DirectorsGlobeNewswireBruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company
5mo agoKYMRKymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual MeetingGlobeNewswireOral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies KT-621 parallel Phase 2b
5mo agoKYMRKymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi CollaborationGlobeNewswireFirst-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR),
5mo agoKYMRKymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development OperationsGlobeNewswirePenny Carlson will oversee global clinical development operations across Kymera's oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June 08, 2026 (GLOBE
5mo agoKYMRKymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS CongressesGlobeNewswireKT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial ongoing, with
5mo agoKYMRJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - KYMERA THERAPEUTICS INCEarnings Call TranscriptsAll right, thanks. All right. Good morning to everyone in the room and on the webcast. My name is Faisal Khurshid. I'm one of the senior biotech analysts here at Jefferies. Really pleased to kick off this first morning o
5mo agoKYMRKymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
6mo agoKYMRKymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society CongressesGlobeNewswireLate-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases KT-621 parallel
6mo agoKYMR2026 GLOBAL HEALTHCARE CONFERENCEKYMERA THERAPEUTICS INCEarnings Call TranscriptsOkay. Let's get started. So good morning, everyone. Welcome back to the Bank of America Healthcare Conference. I am Tazina Mudd. I'm one of the senior biotech analysts here at the bank. For the next 30 minutes, we'll be
6mo agoKYMRKymera Therapeutics to Participate in Upcoming May Investor ConferencesGlobeNewswireWATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
6mo agoKYMRKymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease WeekGlobeNewswireKT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models KT-579 Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 WATERTOWN, Mass., May
6mo agoBIIB KYMRJeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, TalentBusiness WireHighly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio development
6mo agoKYMRFirst Quarter 2026 Results Call - Kymera TherapeuticsEarnings Call Transcripts🎵outro music plays🎵 Thank you. Thank you. Thank you. We'll be right back. Thank you. Thank you. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Good day everyone, my na
6mo agoKYMRKymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business UpdateGlobeNewswireKT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the
6mo agoKYMRKymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswireWATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
7mo agoKYMRKymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe AsthmaGlobeNewswireKT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track designation
7mo agoKYMRKymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development CandidateGlobeNewswireKT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass., April 09, 2026
7mo agoKYMRKymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewswireFeatured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621's compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma,
8mo agoKYMRKymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewswireWATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
8mo agoKYMRKymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateGlobeNewswireKT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579
8mo agoKYMRKymera Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswireWATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
8mo agoKYMRKymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewswireWATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
9mo agoKYMRKymera Therapeutics to Participate in Upcoming February Investor ConferencesGlobeNewswireWATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
9mo agoKYMRKymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 DegraderGlobeNewswireData from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass.,
10mo agoKYMRKymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsGlobeNewswireKT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in